Abstract-The experience with transcatheter aortic valve replacement is increasing worldwide; however, the incidence of potentially catastrophic cardiac or aortic complications has not decreased. In most cases, significant injuries to the aorta, aortic valve annulus, and left ventricle require open surgical repair. However, the transcatheter aortic valve replacement patient presents a unique challenge as many patients are at high or prohibitive surgical risk and, therefore, an open surgical procedure may not be feasible or appropriate. Consequently, prevention of these potentially catastrophic injuries is vital, and practitioners need to understand when open surgical repair is required and when alternative management strategies can be used. The goal of this article is to provide an overview of current management and prevention strategies for major complications involving the aorta, aortic valve annulus, and left ventricle. (Circ Cardiovasc Interv. 2017;10:e004735.
T he use of transcatheter aortic valve replacement (TAVR) continues to grow worldwide, with over 100 000 procedures performed between 2002 and 2013. 1 Despite increased operator experience, evolution of the technique, and deflectable catheters, major complications still occur in ≤6% to 8% of cases. [2] [3] [4] Such major complications have been associated with a 2-to 3-fold increase in 30-day mortality. [5] [6] [7] Complications specifically involving the aorta, aortic valve (AV) annulus, or left ventricle (LV) are rare, occurring in only 0.2% to 1.1% of cases. 8 However, such complications are potentially catastrophic and present unique management challenges in the TAVR population. Management of injuries to these structures usually requires open surgical repair; however, TAVR patients are frequently at high or prohibitive surgical risk before the complication. Consequently, an attempted invasive, open surgical repair may not be appropriate. In this review, we present the current knowledge on prevention, diagnosis, and management of these complications.
Aortic Dissection and Perforation
Thoracic aortic dissection is one of the most lethal events in cardiovascular disease, and there are numerous possible mechanisms by which an aortic dissection can develop during TAVR: stiff wire interaction in the ascending aorta, catheter valve injury to the aortic wall by creating an intimal disruption, valve retraction to expose the balloon in balloon-expandable systems, balloon valvuloplasty injury, or postdilation balloon interaction with the aorta. If left untreated, mortality from type A aortic dissection (TAAD; Figure 1 ) is ≈7% in the first hour after symptom onset and rises to as much as 90% by 24 hours. 9, 10 Despite its more benign reputation, type B aortic dissection (TBAD) also causes significant morbidity and mortality. In a review of the International Registry of Aortic Dissection (IRAD), overall in-hospital mortality was 13% after TBAD and remained as high as 10% in patients who could be initially managed medically. 11 TBAD similarly can be caused by stiff wire injury in the descending thoracic aorta, valve interaction during passage, during docking a SAPIEN valve on the balloon, or potentially even by microscopic intimal injuries that subsequently progress in the setting of severe hypertension. Fortunately, aortic dissection during TAVR is a rare complication, reported in only 0.2% of cases in a recent, large report from the German Aortic Valve Registry (GARY). 12 Our institutional experience is similar, with aortic dissection occurring in 0.3% of TAVR cases. Because TAVR requires the introduction of multiple wires and devices into the abdominal and thoracic aorta, there is a risk of other aortic injuries, in addition to dissection. Reports of such injuries are
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limited by small numbers, with only 1 specific aortic perforation reported in the Placement of Aortic Transcatheter Valves trial (PARTNER) database. 13 In our institutional experience, 3 patients experienced an aortic perforation or rupture during TAVR.
Aortic Dissection Management
Because of the high early mortality associated with TAAD, the standard of care is open surgical repair. In contrast, TBADs are usually managed medically, except in cases of serious complications such as visceral malperfusion. However, TAVR patients present a particular management challenge because they are oftentimes at high risk for further morbidity or mortality from an open procedure. To date, there have been no large series specifically examining the management of aortic dissection after TAVR. In our own institutional experience, 3 of 4 TAADs were managed medically because of the assessment that the risk of an open repair outweighed the risk of medical management alone. These 3 patients all had a similar presentation: no major hemodynamic compromise without pericardial effusion, minimal to low flow in the false lumen, and dissection limited to the outer curve of the ascending aorta. The left main ostium seemed partially at risk for compromise in one of these patients because of the location of the dissection, prompting left main stenting for the protection of the ostium. The exception was a patient with a Society of Thoracic Surgeons (STS) score of 3.2% who underwent successful definitive surgical repair with ascending aorta and hemiarch replacement-surgical repair was prompted on the basis of a pericardial effusion, hemodynamic compromise, and a large false lumen with flow, extending down to the thoracic and abdominal aorta. Both of the 2 TBADs we have experienced were managed medically because there were no associated complications.
In the absence of any significant data on the management of aortic dissections in the TAVR population, the general standards of care should be followed. However, careful weighing of the risks and benefits of a complex open procedure versus medical management is essential. Regardless of the eventual management plan, all dissection patients should have intensive medical therapy, including admission to the intensive care unit for strict heart rate and blood pressure control using intravenous β-blockers to maintain a heart rate and systolic blood pressure of <60 bpm and 120 mm Hg, respectively. If β-blockade is contraindicated or poorly tolerated, a dihydropyridine calcium channel blocker or sodium nitroprusside can be used.
Interestingly, previous case reports have described the successful use of thoracic endografts in the ascending aorta to treat TAAD. [14] [15] [16] This technology remains to be fully developed, however, as effectively placing an endograft depends on patient anatomy, including the dissection's origin and extent, the size of the aorta/sinotubular junction, and the anatomy of the arch. It is expected that ascending aortic endograft technology will mature in the near future and may be an ideal solution in cases of TAVR-induced TAAD.
Aortic Perforation Management
In cases of aortic perforation, management is largely determined by the patient's clinical status and the location of the perforation. In our experience, 1 injury occurred because of perforation of the right sinus of Valsalva by a calcified native valve leaflet. The chest was opened because of significant hypotension; however, the bleeding was controlled after administration of protamine sulfate and application of manual pressure. In a second case, a free perforation occurred in the infrarenal abdominal aorta, which also led to rapid hemodynamic compromise. This perforation likely resulted from the edge of a split E-sheath perforating a highly tortuous aorta, and it was immediately repaired by placing an aortic stent graft after vascular control was achieved with a large aortic occlusion balloon inserted peripherally. In the third case, the patient suffered a contained aortic rupture at the level of the 12th thoracic vertebra. This patient had an initial STS score of 20.8%, and because of the prohibitive risk associated with any further intervention, the rupture was managed medically.
Aortic Dissection and Perforation Outcomes
There have been no studies in the literature to date that specifically report outcomes after aortic dissection during TAVR; however, outcomes can be generalized from several large studies examining high-risk patients and those with iatrogenic dissections. In the largest study of TAAD in the elderly, Mehta et al 17 from IRAD reported 52.5% in-hospital mortality for patients >70 who were medically treated for TAAD and 37.5% in-hospital mortality for those managed surgically. Furthermore, in-hospital mortality for medically managed patients older than 80 was 45.5% and 62.5% if older than 85. 17 The mortality in the IRAD database is higher than that reported in several smaller, single-institution surgical series, but it is likely more representative of the overall experience. [18] [19] [20] In our institutional experience, all patients with an aortic dissection survived to hospital discharge, with a median survival of 493 days. Although the number of patients is small, these outcomes are excellent given the extreme mortality associated with aortic dissection in the literature and the fact that all patients were >80 years old, with 2 patients >90. The lower mortality in our institutional series may be because of important differences between TAVR patients and those in the IRAD registry. Only 11% of the elderly patients in the IRAD study suffered an iatrogenic dissection, whereas all the dissections in our series occurred during or after TAVR. Although iatrogenic aortic dissections are associated with higher mortality than spontaneous dissections, the rapid diagnosis and treatment that is possible during TAVR may help stabilize a dissection and minimize complications from malperfusion or tamponade. This is consistent with the findings from a meta-analysis of outcomes after iatrogenic TAAD by Jonker et al, 21 which found intraoperative diagnosis to be protective against in-hospital death.
It is important to note that no patients in our experience developed malperfusion syndromes, myocardial infarction, or stroke, which are all known predictors of death after TAAD. 10 However, the absence of these complications cannot be solely attributed to early detection and treatment, and 1 patient developed a TAAD on postoperative day 5. Consequently, although the absence of such serious additional complications in these dissection patients certainly contributed to the observed outcomes, the ability to rapidly diagnose and treat aortic dissections during TAVR may improve results of medical management.
Overall, the small number of reported cases of aortic dissection during TAVR severely limits any conclusions on optimal management strategies. However, as seen in our institutional experience, the absence of in-hospital mortality and overall postoperative survival of >1 year in our high-risk, elderly patients demonstrates that medical management is not futile or solely palliative and suggests that it may be a reasonable therapeutic option in the TAVR population.
Aortic Dissection and Perforation Prevention
Ascending and descending thoracic aorta dissection and perforation are generally caused by catheter/wire trauma and vascular sheath insertion, although dissection can also develop after aortic valvuloplasty. 22 Recent reductions in the size of sheaths and delivery systems decrease the risk of direct catheter injury. However, careful evaluation of aortic calcification, tortuosity, and size is required before all procedures, and particular care is needed when placing sheaths and advancing catheters in markedly ectatic vessels.
AV Annular Rupture
Rupture of the AV annulus ( Figure 2) is a rare complication of TAVR, occurring in <1% of cases. 23, 24 However, the potential for rapid hemodynamic collapse because of cardiac tamponade makes it one of the most feared. Annular rupture is most commonly reported during implantation of balloon-expandable valves or during postimplantation dilation of self-expanding valves. 22, [24] [25] [26] The presentation is variable, ranging from a thickening of the aortic wall or small pericardial effusion to immediate tamponade and rapid cardiac arrest. In our institutional experience, annular rupture occurred in 5 patients (0.3%).
Annular Rupture Management
In the event of annular rupture during TAVR, the management strategy is dictated by the patient's clinical status. If the patient is hemodynamically unstable because of cardiac tamponade, emergent surgical repair is required. In our institutional experience of 5 annular ruptures, 3 rapidly developed cardiac tamponade and required open surgery. Unfortunately, one of these patients had a porcelain aorta and could not undergo surgical repair; however, the other 2 patients had successful open repairs using a pericardial patch. It is vital to determine the cause of hemodynamic instability, however, as annular rupture can also cause a root hematoma and compress a coronary artery. This has been previously reported and was successfully managed with placement of a coronary stent. 27 If there is an annular rupture but the patient remains hemodynamically stable, there is time for further evaluation of the injury and consideration of different management options. If the injury is limited and there is no evidence of pericardial effusion, a conservative approach may be used. 22, 24, 26, 28, 29 In such cases, it is important to correct any coagulopathy and closely monitor the patient with serial imaging. Serial computed tomographic scans are the most accurate and least invasive because transthoracic echocardiography may be unable to detect injuries previously seen using transesophageal imaging. 23, 28, 30 If there is a pericardial effusion but no evidence of tamponade, placement of a pericardial drain may be sufficient; however, close monitoring remains essential.
Lastly, in cases where conservative management or isolated pericardial drainage is not sufficient and the patient is not able to undergo surgical repair, transcatheter techniques can be attempted. In our experience, 2 annular ruptures were successfully repaired by placing a second TAVR device as a valve-invalve to cover the rupture site. However, there are important limitations to this strategy. First, it is only possible when the injury is limited to the annular complex and does not extend into the LV outflow tract. Second, the use of a valve-in-valve technique is not possible if a large subannular defect is present, and it is not recommended if the patient is thought to be able to safely undergo surgery. 23 However, in select cases when open surgical repair is not possible (eg, extreme risk, reoperation, or hostile chest) or the patient has been in prolonged extremis, a valve-invalve technique is an excellent salvage option and has been successfully performed at both our and other centers. 31 Additional techniques, such as the use of N-butyl-2-cyanoacrylate glue to seal the rupture site by Piliero et al, 32 have been reported; however, we do not have any experience with them.
Annular Rupture Outcomes
Annular rupture is a catastrophic complication and carries a significant risk of mortality. In the Sapien Aortic Bioprosthesis European Outcome registry (SOURCE), emergent cardiac surgery during TAVR was associated with a 30-day mortality of ≈52%, and there was 100% mortality in patients with aortic annular rupture or tamponade. 33 Other series have reported a wide range of 30-day survival; however, when taken together, survival for patients with annular rupture or tamponade is ≈50%. 23, 25, [34] [35] [36] [37] [38] Our experience is consistent with these previous reports, highlighting both the importance of avoiding such injuries and having the capability to perform emergency cardiac surgery, because patient salvage is possible even though mortality remains extreme.
Annular Rupture Prevention
Given the significant mortality associated with annular rupture, prevention is paramount, and the first step should be identifying patients who are at particular risk. In multiple reports, many potential risk factors for annular rupture have been identified, including an AV annulus diameter of <20 mm, severe asymmetrical subaortic LV hypertrophy, diffuse LV hypertrophy in elderly patients, and significant calcification of the annulus, LV outflow tract, sinuses of Valsalva, or AV leaflets. 23, 25, 26, 39, 40 Few patient or procedural characteristics have proven predictive of annular rupture. However, in a multicenter study of balloon-expandable transcatheter valves, Barbanti et al 26 found that moderate or severe subannular/ LV outflow tract calcification, as determined by an elevated Agatson score, and prosthesis area oversizing by >20% were independently associated with annular rupture. These 2 factors should be examined in all TAVR patients.
Although the need for significant oversizing may decrease with the introduction of new TAVR devices, which have shown more tolerance for undersizing, the presence of significant calcium burdens is unlikely to change. 41 In our practice, as a further precaution in patients at high risk for rupture (eccentric bulky leaflets, need for oversizing, extremely frail, or small annuli), we routinely use serial aortic dilatation during balloon-expandable TAVR. This involves active surveillance of the aortic sinus and annulus by transesophageal echocardiography during deployment.
The decision to stop inflation is made in part on visualizing protrusion of calcium into the aortic wall. Postdilatation is then performed after a short period with a small or slightly higher volume, as needed, with the rationale that slow aortic expansion allows stretch of the aortic wall and may reduce the risk of rupture (Figure 3 ).
LV Injuries
The introduction of the valve device and stiff guide wires into the aortic root and LV during TAVR raises the potential for injuries to the ventricle. Such injuries are infrequent, with cardiac perforation occurring in 1.3% of patients in the CoreValve trial. 1 The clinical presentation can be highly variable, ranging from rapid-onset cardiac tamponade to an indolent LV pseudoaneurysm. In our institutional experience, the LV was injured in 3 patients, resulting in 2 ventricular perforations and 1 LV pseudoaneurysm (Figure 4 ).
LV Injury Management
Management of LV injuries is highly specific and depends on the type of injury, the injury location, the patient's clinical status, and the patient's overall health status and ability to tolerate an open repair. Both of the patients with free LV perforation in our series developed rapid cardiac tamponade and consequently required sternotomy and emergent open repair, whereas the LV pseudoaneurysm was closed with a percutaneously placed vascular plug. This range of management options is consistent with the published reports of LV injuries during TAVR. [42] [43] [44] [45] As is true with other periprocedural injuries, perforation leading to cardiac tamponade requires open exploration and repair unless the patient is not deemed to be a candidate for even salvage cardiac surgery. If the patient is hemodynamically stable but has a pericardial effusion, percutaneous mediastinal drainage may be possible; however, close monitoring of the drainage volume and clinical status is necessary to make sure the perforation seals. In cases of LV pseudoaneurysm, repair using a percutaneously placed vascular plug has been reported by several groups with good results. [42] [43] [44] 46, 47 However, the procedure is not without its own potential complications, and there are published reports of transient aphasia because of pseudoaneurysm thrombus embolization, acute myocardial infarction from device occlusion of the left circumflex artery, and device embolization itself. 42, 48, 49 Surgical closure is possible, however, as is true with other peri-TAVR injuries, this is complicated by the high-risk nature of the patient population. Minimally invasive surgical repair via a left thoracotomy has been described and may be a good alternative approach in TAVR patients. 50 Of note, right ventricular perforation because of improper temporary pacemaker lead placement occurs infrequently, though the true incidence is difficult to quantify given the numerous causes for a new pericardial effusion. Right ventricular perforation can almost always be managed conservatively or with pericardiocentesis; the use of balloon-tipped pacemaker leads may reduce this frequency given the decreased catheter stiffness and balloon safeguard. No patient in the current series required surgical exploration for right ventricular perforation.
LV Injury Outcomes
There are few reports in the literature that specifically address outcomes after LV injury during TAVR, and they are primarily individual case reports. Not surprisingly, patients who develop cardiac tamponade requiring open surgical exploration or repair have dismal outcomes, whereas outcomes are far superior in patients who remain hemodynamically stable and are able to undergo conservative management or percutaneous repairs. [43] [44] [45] These results are consistent with our own 
LV Injury Prevention
Stiff wires used during retrograde approaches can perforate the LV. Aside from careful placement, this is best avoided by using an appropriately curved stiff wire with a J-curve at the tip and closely monitoring the transition point from the soft tip to stiff wire segment in the LV. 22 These techniques, as well as careful attention to wire manipulation, should prevent most LV injuries. It is also important to monitor the wire position during any balloon inflation. In the cases from our institutional series, the ventricular perforations likely occurred because of the balloon advancing a stiff wire during balloon aortic valvuloplasty because the patients had tortuous aortas requiring 2 stiff wires in the ventricle that could have had residual, builtup tension.
Iatrogenic Ventricular Septal Defect
Ventricular septal defect (VSD) after TAVR is a rare complication, with a recent systematic review identifying only 20 reported cases. 51 Post-TAVR VSD most often results from a focal annular rupture that extends into the right ventricular outflow tract, but direct trauma to the septum from the new valve, delayed rupture of scar tissue from periprocedural injury, and changes in the tensile forces experienced by the septum after valve implantation have all been described as mechanisms. [51] [52] [53] The clinical presentation and time to diagnosis can vary significantly. In their review, Ando et al 51 found a median time to diagnosis of 7 days after TAVR, with the clinical presentation ranging from asymptomatic to new-onset dyspnea and heart failure.
Management and Outcomes of Post-TAVR VSD
VSDs can usually be managed conservatively as long as patients remain asymptomatic and without a history of endocarditis. 51, [54] [55] [56] If the VSD is symptomatic and requires intervention, percutaneous closure should be the first option given the high-risk TAVR patient population and the high success rate and low incidence of complications associated with percutaneous closure. [57] [58] [59] [60] [61] [62] [63] In the only review published to date, 4 of the 20 patients (20%) died; however, there were no deaths among the patients who underwent VSD closure, and all were clinically stable at a median follow-up of 7.5 months. 51 Most post-TAVR VSDs are located close to the prosthetic valve, and it has been hypothesized that percutaneous closure devices could interfere with valve function or displace the valve itself. 51 However, to date, there have been no reports of such occurrences. 
Institutional Experience and Outcomes
A summary of our institutional experience is presented in Tables 1 through 3 . All patients who underwent TAVR at our institution between 2007 and July 2016 were retrospectively reviewed (n=1756), and 17 patients with major complications involving the aorta, AV annulus, or ventricle were identified and included (0.97%). Several additional patients who developed periaortic hematomas have been previously reported. 29 All complications were defined according to the Valve Academic Research Consortium II definitions. 64 Clinical, follow-up, and mortality data were collected from institutional electronic medical records. The STS risk score was calculated using the Online STS Adult Cardiac Surgery Risk Calculator. 65 Baseline patient characteristics are presented in Table 1 . The mean age was 85.4±8.0 years (range 63-94 years), with women comprising 70.6% of the cohort. The preoperative mean AV area was 0.6±0.1 cm 2 , and the average mean AV gradient was 52.4±13.2 mm Hg. Patients presented with a mean LV ejection fraction of 55±14%, and 71% had New York Heart Association Class III heart failure symptoms. The mean STS score was 7.5±6.2. Representative movies of all patients' angiograms and echocardiograms are available in the Data Supplement.
Overall Postoperative Outcomes and Survival
Postoperative outcomes are presented in Table 3 . Thirty-day or in-hospital mortality was 23.5% (n=4), with a median survival of 241 days. Median overall length of stay was 8 days, with a median of 5 days spent in the intensive care unit. The most common postoperative complications were new-onset atrial fibrillation and respiratory failure, which occurred in 35.3% and 23.5% of patients, respectively. There were no periprocedural myocardial infarctions or strokes. One patient (5.9%) required a new permanent pacemaker. One patient (5.9%) developed renal failure requiring hemodialysis. Four patients (23.5%) required a reoperation for bleeding. Inhospital death was because of cardiogenic shock in 2 cases, hypovolemic shock in 1 case, and septic shock in 1 case. Cause of death was not available for patients who died outside the hospital.
Postoperative Outcomes and Survival After Specific Complications
There was no in-hospital or 30-day mortality in patients who developed an aortic dissection, whereas 2 of the 3 patients (66.7%) with aortic perforation/rupture and 1 of the 5 patients (20.0%) with AV annular rupture died during their initial hospitalization. Patients with an aortic dissection survived for a median of 493 days (interquartile range of 280-771 days); however, patients with an aortic perforation/rupture had a median survival of only 6 days (6-724 days), and those with an annular rupture survived for a median of 44 days (12-241 days).
Summary
TAVR has revolutionized the treatment of AV disease and will likely only continue to grow in popularity as indications expand. Significant complications, such as those discussed here that affect the aorta, AV annulus, and LV, present a 
